Juan Rondán
A5040941013- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Valve Diseases and Treatments
- Vascular Procedures and Complications
- Lipoproteins and Cardiovascular Health
- Cardiac, Anesthesia and Surgical Outcomes
- Aortic aneurysm repair treatments
- Venous Thromboembolism Diagnosis and Management
- Peripheral Artery Disease Management
- Atrial Fibrillation Management and Outcomes
- Central Venous Catheters and Hemodialysis
- Cerebrovascular and Carotid Artery Diseases
- Pharmaceutical Economics and Policy
- Infective Endocarditis Diagnosis and Management
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac Arrest and Resuscitation
- Coronary Artery Anomalies
- Mechanical Circulatory Support Devices
- Aortic Disease and Treatment Approaches
- Cardiac Structural Anomalies and Repair
- Cardiac and Coronary Surgery Techniques
- Cardiac Arrhythmias and Treatments
- Medication Adherence and Compliance
Hospital Universitario De Cabueñes
2015-2024
University Hospital Complex Of Vigo
2021
Hospital Universitario Virgen de las Nieves
2018
Central University Hospital of Asturias
2003-2012
Hospital Universitari Sant Joan D'Alacant
2011
Previous evidence supports that monoclonal antibodies inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein cholesterol (LDLc) by 50%-65%, regardless of baseline treatments. We tested possible sex differences in a multicentre registry real-world patients treated with PCSK9 inhibitors.This is and retrospective study 652 initiating treatment any inhibitor 18 different hospitals. Before-treatment on-treatment LDLc medical treatments, clinical...
Monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein cholesterol (LDLc) by 55%, regardless of baseline treatments. Nonetheless, effect other lipid parameters, such as remnants or, so-called residual risk, is unknown.Multicenter and retrospective registry patients treated with PCSK9 inhibitors from 14 different hospitals in Spain. Before on-treatment parameters were recorded. Residual risk was estimated (1) remnants, (2)...
We aimed to compare the performance of recent CASTLE score J-CTO, CL and PROGRESS CTO scores in a comprehensive database percutaneous coronary intervention chronic total occlusion procedures.Scores were calculated using raw data from 1,342 procedures included REBECO Registry that includes learning expert operators. Calibration, discrimination reclassification evaluated compared.Mean values were: 1.60±1.10, J-CTO 2.15±1.24, 1.68±0.94 2.52±1.52 points. The overall success rate was 77.8%....
Abstract: Low-density lipoprotein cholesterol (LDLc) is the lead effector of atherosclerosis and main treatment target. Bempedoic acid a novel oral drug in therapeutic armamentarium which able to reduce LDLc. The objectives this study were (1) select potential patients for administering bempedoic such as those with very high cardiovascular risk LDLc not achieved despite conventional PCSK9 inhibitors (PCSK9i) and/or statins ezetimibe (2) estimate cost-effectiveness different scenarios....